Get the Stockscreener App
4.10
2.50%
0.10
After Hours:
4.04
-0.06
-1.46%
Precision Biosciences Inc stock is traded at $4.10, with a volume of 211.46K.
It is up +2.50% in the last 24 hours and down -2.38% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$4.00
Open:
$4.04
24h Volume:
211.46K
Relative Volume:
0.98
Market Cap:
$98.69M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-6.2121
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
+6.49%
1M Performance:
-2.38%
6M Performance:
-20.08%
1Y Performance:
-25.05%
1-Day Range:
$3.9822
$4.185
1-Week Range:
$3.69
$4.185
52-Week Range:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.10 | 96.29M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Update Report: Is GSLPRB still a buy after recent gainsExit Point & Fast Moving Market Watchlists - baoquankhu1.vn
Block Trades: Is Precision BioSciences Inc a speculative investmentBear Alert & Expert Approved Trade Ideas - baoquankhu1.vn
What’s the outlook for Precision BioSciences Inc.’s sector2025 Bull vs Bear & Expert Curated Trade Setups - mfd.ru
Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares - MarketBeat
John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock - MarketBeat
Downgrade Watch: What is the long term forecast for Precision BioSciences Inc stockQuarterly Portfolio Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
FDA Clears ARCUS Editor for Duchenne Hot-spot - CRISPR Medicine News
Top 15 Female Motivational Speakers in the UK Revealed in 2026 Shortlist - Weekly Voice
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial - Indian Pharma Post
Precision BioSciences receives U.S. FDA clearance of investigational new drug application for first-in-class PBgene-Dmd for treatment of Duchenne muscular dystrophy - marketscreener.com
Precision Biosciences’ PBGENE-DMD cleared to enter clinic - BioWorld MedTech
Precision BioSciences Receives FDA Clearance for PBGENE-DMD Program - TradingView
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy - Business Wire
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A 54% Potential Upside in the Precision Medicine Oncology Space - DirectorsTalk Interviews
Aug Catalysts: Is Precision BioSciences Inc likely to announce a buybackMarket Risk Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Update - MarketBeat
Aberdeen Group plc Acquires Significant Stake in Precision BioSciences Inc - GuruFocus
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Finviz
Aug Decliners: Can WRLD weather a recessionMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Signal Recap: Is Precision BioSciences Inc likely to announce a buybackWeekly Trading Summary & Intraday High Probability Alerts - baoquankhu1.vn
Chart Watch: Should I average down on KDLY stock2025 Market Overview & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Precision BioSciences launches $75M stock and warrant offering - MSN
Aug Mood: What is DURECT Corporations book value per shareWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Precision Biosciences chief research officer Smith sells $41k in shares - Investing.com Nigeria
Michael Amoroso Sells 34,799 Shares of Precision BioSciences (NASDAQ:DTIL) Stock - MarketBeat
Precision BioSciences (NASDAQ:DTIL) Insider J. Jefferson Smith Sells 10,200 Shares - MarketBeat
Precision BioSciences (NASDAQ:DTIL) CFO Sells $61,308.39 in Stock - MarketBeat
Precision Biosciences CFO sells $61k in shares By Investing.com - Investing.com UK
Precision Biosciences chief research officer Smith sells $41k in shares By Investing.com - Investing.com Nigeria
Scimeca, Precision Bio general counsel, sells $35,681 in DTIL stock By Investing.com - Investing.com Canada
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Precision BioSciences (NASDAQ:DTIL) Trading Down 3.8%Time to Sell? - MarketBeat
Guidance Update: Is Precision BioSciences Inc stock trending bullishIPO Watch & Pattern Based Trade Signal System - baoquankhu1.vn
Aug Levels: How does Precision BioSciences Inc perform in inflationary periods2025 Dividend Review & Fast Gain Swing Alerts - baoquankhu1.vn
Trend Recap: Will Precision BioSciences Inc stock benefit from green energy trends2025 Price Action Summary & Technical Pattern Based Signals - Bộ Nội Vụ
Precision BioSciences Highlights 2026 Gene Editing Priorities - TipRanks
Precision BioSciences advances gene editing programs with key milestones By Investing.com - Investing.com Nigeria
Aug Catalysts: Is Precision BioSciences Inc stock trending bullishPortfolio Value Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
Precision BioSciences advances gene editing programs with key milestones - Investing.com
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy - Business Wire
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform - GlobeNewswire
Precision BioSciences Shares Surge Following FDA Rare Pediatric Disease Designation - MSN
Will Precision BioSciences Inc. stock outperform Nasdaq indexMarket Performance Recap & Detailed Earnings Play Alerts - ulpravda.ru
Can Precision BioSciences Inc. (PBS0) stock deliver strong annual returns2025 Short Interest & Accurate Buy Signal Alerts - Улправда
Can Precision BioSciences Inc. stock reach $100 price targetJuly 2025 Price Swings & Verified Swing Trading Watchlists - Улправда
Is Precision BioSciences Inc. stock a top pick in earnings seasonEarnings Performance Report & AI Driven Price Forecasts - Улправда
Will Precision BioSciences Inc. stock split again soon2025 Winners & Losers & Low Drawdown Investment Strategies - Улправда
How Precision BioSciences Inc. stock compares to market leadersWeekly Market Outlook & Smart Swing Trading Techniques - Улправда
Can Precision BioSciences Inc. stock hit analyst price targetsQuarterly Trade Review & Low Drawdown Investment Ideas - Улправда
Is Precision BioSciences Inc. (PBS0) stock a top hedge fund pickIPO Market Watch & Free High Yield Investment Strategies - Улправда
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
1.52%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):